Last year we reported the FDA approval and then U.S. launch of Inflectra®, a biosimilar of Remicade® (infliximab). This week, Pfizer and Celltrion Healthcare have reported that the results of a Phase 3 study of Inflectra demonstrated that “switching patients with Crohn’s disease (CD) to Inflectra from Remicade® (infliximab) led to comparable efficacy, safety and tolerability to treatment with Remicade® over a 24 week period.” The results also demonstrated that Inflectra® was well-tolerated, with a similar safety profile to Remicade®.
Full results were presented at the 25th United European Gastroenterology Week conference that took place over this past weekend in Barcelona.